Key result
Intravenous levosimendan significantly reduced P-wave dispersion from 40 msec to 30 msec (P<0.001) in patients with acute decompensated heart failure, whereas dobutamine had no effect.
Why the study?
Does intravenous levosimendan reduce P-wave dispersion compared to intravenous dobutamine in patients with acute decompensated heart failure?
RCT (n=40)
Does intravenous levosimendan reduce P-wave dispersion compared to intravenous dobutamine in patients with acute decompensated heart failure?
p-value: p=<0.001
Levosimendan infusion significantly reduces P-wave dispersion compared to dobutamine in patients with acute decompensated heart failure, suggesting potential electrophysiological benefits.
Levosimendan may lower atrial arrhythmia risk versus dobutamine in acute decompensated HF; extends its benefits to electrophysiological effects.
We aimed to evaluate the comparative effects of levosimendan and dobutamine on P-wave dispersion (PWD) in the patients with acute decompensated heart failure (ADHF). Materials and methods: The study population consisted of 40 patients (mean age = 68 years, 23 men, NYHA class III-IV) presented with ADHF. Patients were randomized to intravenous levosimendan (n = 20) or dobutamine (n = 20) groups. The P-wave duration measurements were calculated in 12-lead surface ECG simultaneously and recorded before and after treatment. Manual measurements of P-wave duration were performed with digital calipers on a high resolution computer screen by two cardiologists not aware of the patients' clinical data. Results: There were no significant changes in P max in the dobutamine group whereas a significant decrease was observed in the levosimendan group after the infusion. The levosimendan infusion significantly reduced PWD (from 40 msec to 30 msec, P < 0.001) but the dobutamine infusion has no effect on PWD. In hospital new onset atrial fibrillation (AF) frequency was similar among two groups. Conclusion: Levosimendan infusion significantly reduces PWD compared to dobutamine infusion in our study population. This finding may be related to hemodynamic improvements provided by levosimendan.
No takes yet. Share an insight, caveat, or question.
Iyısoy et al. (2010) conducted an RCT in acute decompensated heart failure (n=40). Levosimendan vs. Dobutamine was evaluated on P-wave dispersion (p=<0.001). Intravenous levosimendan significantly reduced P-wave dispersion from 40 msec to 30 msec (P<0.001) in patients with acute decompensated heart failure, whereas dobutamine had no effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: